Events

Loading Events
Find Events

Event Views Navigation

Past Events › Webinars

Events List Navigation

April 2018

The Use of Human iPSC-derived Motor Neurons for Translational Research

Webinars
April 9 | 10:00 am CDT - 11:00 am CDT

In this webinar, Dr. Kevin Eggan will discuss the derivation and characterization of motor neurons from iPS cells and the use of these cells in ALS disease models and translational research. Topics covered: Characterization of iPSC-derived motor neurons Use of iPSC-derived Motor Neurons to generate ALS disease models iPSC-derived Motor Neurons in translational research

Find out more »
January 2018

iPSC-derived Retinal Pigment Epithelial Cells in Research and Clinical Applications

Webinars
January 12 | 1:00 pm CDT - 2:00 pm CDT

In this webinar, Dr. Kapil Bharti discussed the use of induced pluripotent stem (iPS) cell technology to develop in vitro disease models to study patient-specific disease processes, to set up high throughput drug screens, and to develop cell-based therapy for retinal degenerative disease. Topics covered: Characterization of iPSC-derived retinal pigment epithelium (RPE) iPSC-derived RPE for ocular disease modeling iPSC-derived RPE in clinical applications For access to the video recording of this webinar, please register here.

Find out more »
December 2017

Rapid and Reliable Neurotoxicity Detection

Webinars
December 6, 2017 | 9:00 am CDT - 10:00 am CDT

Human iPSC neurons provide robust solutions to predict drug-induced disruption of electrical, structural, and functional processes. Neurotoxicity has been difficult to detect with traditional methods and remains a primary cause of late-stage and post-launch drug attrition. The iCell® portfolio of subtype-specific human neurons provides new models for early and accurate detection of multiple forms of neurotoxicity. This seminar will focus on CDI’s iCell GABANeurons and iCell GlutaNeurons as tools for detecting structural (neurite outgrowth) and electrical (seizurogenesis) toxicities as well…

Find out more »
September 2017

Exploring the Role of iPSC-Cardiomyocytes in Drug Discovery and Safety Assessment

Webinars
September 7, 2017 | 11:00 am CDT - 12:00 pm CDT

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly utilized in drug discovery, safety assessment of pharmaceutical compounds, and studies of disease mechanisms. The opportunity to measure the contractility, viability, and electrophysiology of these cells in real time over extended periods provides researchers with additional mechanistic insights into the roles cardiomyocytes play in both normal development and cardiac disease, in addition to providing incisive information regarding drug efficacy and toxicity. In this special webinar, scientists using hiPSC-CMs will describe novel…

Find out more »
January 2017

Modeling Lipid and Glucose Metabolism Using Human iPSC-derived Hepatocytes

Webinars
January 25, 2017 | 10:00 am CDT - 11:00 am CDT

The study of metabolic disease is changing as limitations of classical in vitro cell models are increasingly evident, causing investigators to search for improved alternatives. Induced pluripotent stem cells (iPSCs) are the logical alternative for advancing basic biology and applied biomedical research through the development of relevant human cell models. Recapitulating native physiological behavior is the ideal scenario for phenotypic screening and target identification—techniques that are paramount to both academic and biopharmaceutical researchers. Join us for this GEN webinar, where we will focus…

Find out more »
December 2016

Advances in Modeling Human Diseases Using Induced Pluripotent Stem Cell-derived Cellular Models

Webinars
December 14, 2016 | 9:30 am CDT - 10:30 pm CDT

A major hurdle in developing relevant disease models for drug discovery is access to the healthy and diseased tissue of interest; induced pluripotent stem cell (iPSC) technology addresses this problem affording access to biologically relevant human tissues in essentially unlimited quantities. In this webinar, we will describe examples of how iPSC-derived disease cell models can be used to understand pathophysiological pathways in disease. Among the examples we will highlight are models of diseases induced in iPSC-derived cells from a healthy…

Find out more »
November 2016

Using Spheroid Models to Develop Relevant High-throughput Assays with Quantitative Endpoints

Webinars
November 3, 2016 | 10:00 am CDT - 11:00 am CDT

Significant advances in automated microscopy, imaging, and biological models are delivering more predictive, physiologically-relevant measurements for drug discovery and environmental toxicity applications. Yet, implementation challenges have been a deterrent for utilizing 3D spheroid models. This webinar will explore the use and analysis of cancer spheroid models, as well as iPSC-derived hepatocyte and cardiomyocyte spheroids for toxicity assessment and demonstrate that historical barriers have been overcome. Join us to learn about: Selecting products and solutions for implementation of 3D spheroid models…

Find out more »
June 2016

Refining Toxicity Testing through Advances in Human iPSC Technology

Webinars
June 9, 2016 | 10:00 am CDT - 11:00 am CDT

Learn how advances in human induced pluripotent stem cell (iPSC) technology enable early detection and avoidance of neuro-, cardio-, and hepatotoxicity during drug development. The Cellular Dynamics line of iCell® products are fully differentiated human cells derived from iPSCs. iCell GlutaNeurons are a population of excitatory neurons that bring previously inaccessible human biology to the lab bench for both discovery and toxicity (seizurogenic) investigations. iCell Hepatocytes 2.0 maintain appropriate function longer than existing models and over extended culture periods, thus…

Find out more »
March 2016

The Promise and Challenges of iPSC Modeling in Parkinson’s Disease

Webinars
March 17, 2016 | 10:30 am CDT - 11:30 am CDT

Abstract Given the challenges of replicating Parkinson’s disease in animal models, returning to models that are human-based and highly clinically characterized may provide the most successful path forward. There is a critical need to differentiate Lewy body Parkinson’s disease from other non-Lewy body forms of parkinsonism. This is important because the underlying molecular pathomechanisms, and hence potential therapeutic targets, are unlikely to be similar for both. One exciting new avenue regarding modeling human disease is the use of induced pluripotent…

Find out more »
December 2015

Advancing PD Cell Therapy: Transplanting Cryopreserved iPSC-derived Neurons

Webinars
December 8, 2015 | 10:00 am CDT

Abstract Cryopreservation of post-mitotic, induced pluripotent stem cell-derived midbrain lineage dopamine neurons (iPSC-mDA) is a significant advancement for cell therapy in Parkinson’s disease. Here, we demonstrate that cryopreserved iPSC-mDA neurons are reliably thawed with excellent viability and maintain biochemical and physiological signatures indicative of human midbrain dopamine neurons. We also examined the engraftment potential of iPSC-mDA neurons after transplantation into both the rodent brain up to 6-months post-grafting and the nonhuman primate brain up to 3-months post-transplantation. Immunohistochemical analysis demonstrated…

Find out more »

CellPress Webinar: New Probes and Sensors in Neurobiology

Webinars
December 7, 2015 | 11:00 am CDT - 12:00 pm CDT

Current efforts in neuroscience are being devoted to mapping activity in defined cells and to developing tools and methods that allow the interrogation of specific circuits in great detail. In this webinar, we will hear from young scientists who will present a snapshot of different techniques and their potential future applications. Viviana Gradinaru will discuss methods to facilitate visualization of circuits and delivery of viral vectors to the brain, Adam Cohen will present advances on all-optical neural imaging, and Bianxiao…

Find out more »
July 2015

Investigative in vitro Drug Toxicology with Human iPSC-derived Cardiomyocytes

Webinars
July 22, 2015 | 11:00 am CDT

Abstract: Human induced pluripotent stem cells (iPSCs) bring human biology into pre-clinical aspects of drug discovery. iPSC-derived cardiomyocytes have emerged as useful tools for detecting and predicting cardiotoxicity and proarrhythmia. The relevant biology of these cardiomyocytes provides a holistic reagent for testing numerous aspects of structural and functional biology, including on- and off-target toxicities. Syncytial hiPSC-derived cardiomyocytes exhibit highly-regular spontaneous beating with low sample-to-sample variation, which makes them adaptable to real-time functional screening in label-free multiwell platforms and facilitates studies…

Find out more »
May 2015

Accurate Prediction of On- and Off-target Cardiotoxicity with Human iPSC-Derived Cardiomyocytes

Webinars
May 27, 2015 | 10:00 am CDT - 11:00 am CDT

Abstract: Latent cardiovascular toxicity issues continue to plague late-stage drug discovery efforts, as well as commercially launched pharmaceutical success. Many current in vitro models lack, or incompletely recapitulate, important aspects of human cardiac biology, thus allowing certain toxicities to escape detection until the non-human primate and clinical trial stages of drug development. Induced pluripotent stem cell (iPSC) technology brings relevant human biology to the laboratory and with it, great promise for early predictive detection of cardiotoxicity. This webinar will encompass…

Find out more »
April 2015

Diabetic Cardiomyopathy Modeling & Screening with iPSC Cardiomyocytes 

Webinars
April 7, 2015

Abstract The development of new medicines for Diabetes Type 2 complications has proven to be challenging due to the use of cellular models that recapitulate some subsets of the specific features of the human disease. Herewith, we develop environmentally and genetically driven in vitro models of the condition using human induced pluripotent stem cell-derived cardiomyocytes. First, we mimic diabetic clinical chemistry to induce a phenotypic surrogate of diabetic cardiomyopathy, observing structural and functional disarray. Next, we consider genetic effects by…

Find out more »
March 2015

Using Human Cardiomyocytes in Phenotypic Screens and Target Verification

Webinars
March 31, 2015

Abstract Induced pluripotent stem cell (iPSC) technology holds great promise for advancing applied and basic biomedical research by bringing relevant human biology into the laboratory. Human cells that can recapitulate native behavior and are amenable to large-scale scientific manipulation, offer a new and highly relevant model for phenotypic screening and target identification; endpoints that are a primary goal of both pharmaceutical and academic endeavors. During their presentations, the panelists will cover recent and ongoing accomplishments utilizing human iPS cell-derived cardiomyocytes.…

Find out more »
December 2014

Efficiently Build Relevant In Vitro Models Using Human Stem Cell-derived Tissue Cells, High Performance Transfection and Novel Multiplexed Reporter Techniques

Webinars
December 9, 2014

Scientific and technical barriers to understanding human biology are being removed. The commercial availability of highly pure human tissue cells, such as iCell® Cardiomyocytes and iCell DopaNeurons, has introduced physiologically relevant cellular models into basic research, early drug discovery and development, and late-stage pre-clinical studies.  Genetic manipulation of these cell models using ViaFect™ Transfection Reagent, an advanced lipid-based transfection technique enabling highly efficient and low toxicity transfection of reporter constructs and markers, offers the opportunity to build relevant human cell…

Find out more »
July 2014

Modeling Chemotherapy-induced Peripheral Neuropathy with Stem Cell Technology

Webinars
July 8, 2014

Abstract With over 28 million cancer survivors worldwide, awareness of long-term toxicities and impact on quality of life in cancer survivors has heightened. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and potentially permanent side effects of modern chemotherapy. The mechanisms underlying CIPN have not been precisely determined, and few human neuronal models to study CIPN exist. This talk highlights: The use of human iPSC-derived neurons as a model to study the effects of chemotherapy on neuronal health…

Find out more »
May 2014

Using Ca2+ Transients as a High Throughput Biomarker for Efficient Detection and Prediction of Drug-induced Cardiac Arrhythmias

Webinars
May 21, 2014

Abstract Find out how iCell Cardiomyocytes and the Kinetic Image Cytometer (Vala Sciences) can detect potential cardiac side-effects earlier in drug development.  

Find out more »
April 2014

Measuring Pharmaco Influences on Human iPSC-derived Neuronal Networks Using a Novel MEA Analysis Tool

Webinars
April 30, 2014

Abstract Neuronal network communication is a key functional characteristic of cultured neurons that is central to the study of psychiatric and neurodegenerative diseases. Combining the induced pluripotent stem cell (iPSC) technology with the multielectrode array (MEA) provides the opportunity to understand fundamental aspects of learning, memory, neuroplasticity, and neuronal disease.

Find out more »
December 2013

Use of Human Induced Pluripotent Stem Cells for Predicting Diverse Cardiotoxicities

Webinars
December 11, 2013

Accurately predicting cardiotoxicity and elucidating the underlying mechanisms remain vexing and expensive problems for drug discovery. This is due, in part, to the wide range of causes and manifestations. Ion-channel block can lead to acute and delayed arrhythmias, while biochemical toxicities can result in cell death, abnormal cardiac function, and even heart failure and death. Finding physiologically relevant, reproducible, and reliable cell models that can be used to detect these end points at preclinical and discovery stages has been a…

Find out more »

Modern Phenotypic Drug Discovery is a Viable Pharma Strategy

Webinars
December 5, 2013

The majority of current drug discovery strategies are directed towards specific, molecular targets.  However, analysis of FDA approved drugs indicates that the majority of first in class new molecular entities (NMEs) originated from phenotypic and not target-directed screening.  Phenotypic drug discovery (PDD) approaches are not commonly used by Pharma due to concerns about assay performance, difficulties with compound structure-activity relationships (SAR), uncertain applicability of chemo-informatics, and the difficulty/requirement for elucidating a molecular target.  We address these perceived issues with PDD…

Find out more »
September 2013

The Value of Phenotypic-based Drug Discovery

Webinars
September 26, 2013

Drug discovery strategies include target-based molecular approaches and phenotypic-based empirical approaches.  Our recent analysis revealed the phenotypic approach as the more successful strategy for first-in-class medicines.  We rationalized that this success was influenced by the unbiased identification of a molecular mechanism of action (MMOA) that contributed to a useful therapeutic index. The value and success of phenotypic approaches will be further increased through efforts to bridge the gap between molecular and phenotypic approaches.  In this webinar I will discuss challenges…

Find out more »

Using Stem Cells to Model Disease

Webinars
September 19, 2013

Reprogramming technology has opened up a new frontier for disease modeling using patient-derived induced pluripotent stem cells (iPSCs). While the prospects of gaining insight into disease mechanisms using human cells seem promising, and identifying potential treatments merely a high throughput screen away, modeling disease in a dish presents its own set of challenges. In addition to validating a meaningful in vitro disease phenotype, modeling complex disease, where the pathogenesis is believed to result from interactions between genes and environmental factors,…

Find out more »
November 2012

iCell® Cardiomyocytes: Using Human Stem Cell-derived Cardiomyocytes to Investigate In Vitro Human Cardiomyocyte Biology

Webinars
November 27, 2012

iCell Cardiomyocytes are human induced pluripotent stem cell-derived (hiPSC) cardiomyocytes that recapitulate the biochemical, electrophysiological, mechanical, and pathophysiological characteristics of native human cardiac myocytes. Using hiPSC technology, Cellular Dynamics International produces a highly pure, highly reproducible, and virtually unlimited supply of human cardiomyocytes. iCell Cardiomyocytes represent a valuable investigative tool to increase our understanding of basic human cardiomyocyte biology and translate that knowledge to improve drug discovery, toxicology, and therapeutic applications. View the webinar on demand.

Find out more »
October 2012

iCell® Neurons: Bringing Relevant Neuronal Biology to the Bench 

Webinars
October 30, 2012

iCell Neurons derived from induced pluripotent stem cells (iPSCs) overcome existing models’ limitations in functionality, purity and reproducibility and offer a virtually unlimited supply of well-characterized cells for drug efficacy screening and safety testing. Importantly, using the iPSC technology to produce neurons enable more biologically relevant disease modeling, improved drug screening strategies, and forward movement toward personalized medicine. View this webinar on demand.

Find out more »
June 2012

CDI/Molecular Devices Webinar: Using Stem Cell-derived Neurons in High Content Screening Assays for Drug Toxicity

Webinars
June 27, 2012

Induced pluripotent stem (iPS) cells are an ideal source of functional human cells that can be manufactured in large quantities to perform drug screening or test for toxic effects on specific target cell types. Human neurons derived from iPS cells, such as iCell® Neurons from Cellular Dynamics International, are very attractive for toxicity studies because they exhibit normal functionality and behavior of mature neurons. During this webinar, we demonstrate the utility of several toxicity screening assays using iCell Neurons with…

Find out more »
May 2012

Using iPSC-derived Cardiomyocytes to Study the Genetics of Left Ventricular Hypertrophy

Webinars
May 21, 2012

Left Ventricular Hypertrophy (LVH) is one of the most potent risk factors for cardiovascular disease (CVD), including ischemic heart disease, chronic heart failure, and particularly CVD death. Cardiac hypertrophy is the response of the myocardium to an increased workload, which usually results from increases in either pressure or blood volume. Numerous lines of evidence suggest that the risk of developing LVH is determined to a significant degree by genetic factors. The overall goal of our research is focused towards identifying…

Find out more »
April 2012

Introduction to iCell® Neurons

Webinars
April 5, 2012

Learn about Cellular Dynamic’s iCell Neurons and how they are innovating life science research. These induced pluripotent stem cell-derived tissues provide an optimal human test system, overcoming the limitations of cadaveric, immortalized cell line, and animal models to advance life science, drug discovery, and biomedical research. View this webinar on demand.

Find out more »

Introduction to iCell® Cardiomyocytes 

Webinars
April 4, 2012

Learn about Cellular Dynamic’s iCell Cardiomyocytes and how they are innovating life science research. These induced pluripotent stem cell-derived tissues provide an optimal human test system, overcoming the limitations of cadaveric, immortalized cell line, and animal models to advance life science, drug discovery, and biomedical research. View this webinar on demand.

Find out more »
December 2011

Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening

Webinars
December 14, 2011

Human tissue cells derived from induced pluripotent stem (iPS) cells recapitulate many of the characteristics and functionality expected of in vivo cell types. iCell® Cardiomyocytes are derived from human IPS cells and are currently being used in both drug discovery and basic research in Industrial and Academic settings. Dr. Eric Chiao of Hoffmann-La Roche Inc. (Roche) will lead this presentation and provide data showing the characterization and utility of iCell Cardiomyocytes, how they are being used in drug development, and…

Find out more »
+ Export Events